Progesterone in Gender Affirming Hormone Therapy Study
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Transgender Women
In brief
This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.
Key facts
- Study ID
- NCT06807580
- Run by
- Emory University
- People needed
- 40
- Starts
- 2025-05-12
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2025-12-24
Who can join
Age: 18 and older, up to 60. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Participants will be transgender women, who have been on gender-affirming hormone therapy for at least 6 months before the start of the study.
You may not qualify if…
- Peanut allergy
- Liver disease (liver enzyme elevations and/or evidence of acute or chronic hepatitis). In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
- Stage 4/5 chronic kidney disease
- Congestive heart failure
- Medical disease or medication use associated with gynecomastia (i.e tumor, hyperthyroidism, chronic kidney disease, cirrhosis, ACE inhibitors, statins, haloperidol, tricyclic antidepressants, atypical antipsychotics)
- Pre-existing cardiovascular disease
- Prior or current history of thromboembolism, known clotting disorders, current or recent anti-thrombotic therapy for venous thromboembolism.
- History of breast cancer
- Prior progesterone use
- Uncontrolled depression and/or suicidal ideation
- Current hypothyroidism (even if controlled with treatment) Progesterone in Gender Affirming Hormone Therapy 9 Version #4, 10/30/24
- Cannabis use of greater than 1 use/week in the past 3 months
- Previously identified BRCA 1 or 2 gene mutation or other familial breast cancer.
- Abnormal mammogram (if indicated - for patients above the age of 50 and on estrogen for 5 or more years OR positive family history of breast cancer) with results of BIRADS 3 or higher. Subjects with a BIRADS 0 mammogram must have undergone additional imaging demonstrating BIRADS 1 or 2 prior to enrollment.
- Have had or are planning to undergo breast enhancement or gender affirming top surgery in the next 6 months
- Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mmHg.
- Triglycerides ≥ 500 mg/dL.
- In our lab, the upper limit of normal for aspartate aminotransferase (AST) is 39, and the upper limit of normal for alanine aminotransferase (ALT) is 52.
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2.
- Estradiol levels outside the stable range (100-300 pg/mL)
- Heavy smoking, defined as 25+ cigarettes per day
- Non-English speaking or those with limited English proficiency
Where it is running
- Emory Transgender Clinic — Atlanta, Georgia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.